Thermo Fisher Scientific Inc.
TMO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $42,879,000 | $42,857,000 | $44,915,000 | $39,211,000 |
| % Growth | 0.1% | -4.6% | 14.5% | – |
| Cost of Goods Sold | $25,151,000 | $25,663,000 | $25,904,000 | $19,577,000 |
| Gross Profit | $17,728,000 | $17,194,000 | $19,011,000 | $19,634,000 |
| % Margin | 41.3% | 40.1% | 42.3% | 50.1% |
| R&D Expenses | $1,390,000 | $1,337,000 | $1,471,000 | $1,406,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $8,676,000 | $8,411,000 | $9,015,000 | $7,910,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10,066,000 | $9,748,000 | $10,486,000 | $9,316,000 |
| Operating Income | $7,662,000 | $7,446,000 | $8,525,000 | $10,318,000 |
| % Margin | 17.9% | 17.4% | 19% | 26.3% |
| Other Income/Exp. Net | -$667,000 | -$1,207,000 | -$862,000 | -$1,481,000 |
| Pre-Tax Income | $6,995,000 | $6,239,000 | $7,663,000 | $8,837,000 |
| Tax Expense | $657,000 | $284,000 | $703,000 | $1,109,000 |
| Net Income | $6,335,000 | $5,995,000 | $6,950,000 | $7,725,000 |
| % Margin | 14.8% | 14% | 15.5% | 19.7% |
| EPS | 16.58 | 15.53 | 17.73 | 19.61 |
| % Growth | 6.8% | -12.4% | -9.6% | – |
| EPS Diluted | 16.53 | 15.45 | 17.64 | 19.46 |
| Weighted Avg Shares Out | 382,000 | 386,000 | 392,000 | 394,000 |
| Weighted Avg Shares Out Dil | 383,000 | 388,000 | 394,000 | 397,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,078,000 | $879,000 | $272,000 | $43,000 |
| Interest Expense | $1,654,000 | $1,491,000 | $726,000 | $536,000 |
| Depreciation & Amortization | $3,108,000 | $3,406,000 | $3,381,000 | $2,592,000 |
| EBITDA | $11,800,000 | $11,195,000 | $11,942,000 | $11,969,000 |
| % Margin | 27.5% | 26.1% | 26.6% | 30.5% |